CLSlsconsensusprocessdependsonexpertswhovolunteertoserveascont『ibutingauthorsand/orasparticipants inthereviewingandcommentingprocess.Attheendofeachcommentperiod,thecommitteethatdeveloped thedocumentisobligatedtoreviewallcomments,respondinwritingtoallsubstantivecomments,andrevisethe ...
2024 ASCO Annual Meeting, LBA4008. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064...
[llntndoeo5krsgsaott1wweisteesntp]hqtmemhe.eirhut.crreeSiapeip,,anAicnntmeeccpgistaroarfblataiaayunuahelrit,tasstluuciuriicnrnralryleenggee.., fdtaTmctaTmcmhahrrllehhsssaaieiienceccoeotccerfrrfsrrkkrroooretieiedieccinniaotaellf-f-oonenyeeascocisoscffntfnvgvugttnttoorrriatururataatlaeerrdt...